whatsmovingnow

CRSP

CRISPR Therapeutics AG

September 17, 2026 · intraday

Rarity
1.83
Peak move
+12.56%
Float cap
$4.6B

CRISPR Therapeutics AG is a biopharmaceutical company that develops gene-based medicines using CRISPR/Cas9 gene editing. Its approved therapy CASGEVY, developed with Vertex, treats eligible patients with severe sickle cell disease or transfusion-dependent beta thalassemia. The company also advances programs in in vivo liver editing, CAR T cell therapies, and regenerative medicine for serious human diseases.

Where do you see this going?

1 vote
Extend100%
Hold0%
Reverse0%

Voting closed at 4:00 PM ET.

What we found

2 events · 0 from SEC or newswire · 0 timed with the move
  • executive_remark

    At the Morgan Stanley 24th Annual Global Healthcare Conference, CEO Sam Kulkarni said the FDA expanded CASGEVY's label to patients aged 2+ (adding ~5,500 eligible patients), cited Vertex's ~$76M quarterly CASGEVY revenue and 100+ patient initiations, and guided to year-end 2026 data for CTX310 Phase 1b, CTX611 Phase 2, and zugo-cel.

    Webnasdaq.comWebau.investing.comWebseekingalpha.com
  • investor_day

    CRISPR Therapeutics announced that senior management, including CEO Samarth Kulkarni, would present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:05 p.m. ET.

    Webnasdaq.com